Improving the Positive Predictive Value of Noninvasive Prenatal Screening (NIPS)

Background
- Noninvasive prenatal screening provides higher detection rates for fetal aneuploidies (the presence of an abnormal number of chromosomes) than do traditional screening methods, such as maternal serum screening.
- For pregnant women at high risk for fetal aneuploidy, the literature reports that using cell-free DNA (cfDNA)-based prenatal screening has the following positive predictive values (PPVs): >90% for trisomy 21, 40% to 68% for trisomy 18, and 45% to 57% for trisomy 13.
- **Objective:** The investigators evaluated the performance characteristics of a technologically advanced cfDNA-based prenatal screening assay (QNatal® Advanced) that incorporates follow-up karyogram analysis in cases with initially abnormal data (elevated “z scores”). They also evaluated initial clinical experience with the assay.

Methods
- An automated cfDNA-based prenatal screening assay for trisomies 21, 18, and 13 was developed. The assay incorporated GC correction to enhance discrimination and Illumina version 4 chemistry.
- The assay was verified (2,085 samples from pregnancies with known aneuploidy status) and validated (667 samples; 552 from women with known singleton and 115 from women with known twin pregnancies).
- These samples included cases of trisomies 21, 18, and 13 and a sex chromosome aneuploidy.
- Results from the first 10,000 clinical samples were analyzed: 180 abnormal results were identified, including trisomies 21, 18, and 13, and Turner syndrome (loss of an X chromosome).

Results
- In verification and validation sets, the assay provided 100% discrimination between affected and unaffected pregnancies for trisomies 21, 18, and 13 (analytical sensitivity and specificity >99.9% for each aneuploidy).
- The assay demonstrated a low “no-call” rate in clinical samples: results could not be reported in 0.88% of samples, including 0.59% because of low fetal fraction and 0.29% because of technical issues.
- In several clinical samples with elevated z scores, follow-up karyogram analysis revealed that the elevations were due to presumably benign maternal duplications rather than true fetal abnormalities. These cases were reported as negative for fetal trisomy.
- The high analytical specificity of the test, and the reduction in false-positive results due to maternal duplications and other factors (eg, uterine fibroids and other maternal copy number variants), yielded high PPVs in cases with clinical follow-up: 100% (41/41 cases) for trisomy 21; 96% (23/24 cases) for trisomy 18; and 69% (9/13 cases) for trisomy 13.

Conclusions
- This technologically advanced cfDNA-based prenatal screening assay demonstrates excellent discrimination between affected and unaffected pregnancies for trisomies 21, 18, and 13.
- Identifying and excluding cases of maternal duplications (and other confounding factors), rather than reporting them as fetal aneuploidies, resulted in high PPVs in clinical practice.

Article published in PLOS ONE

Authors
Charles M Strom, Ben Anderson, David Tsao, Ke Zhang, Yan Liu, Kayla Livingston, Christopher Eizinga, Matthew Evans, Quoclinh Nguyen, David Wolfson, Charles Rowland, Paula Kolacki, Megan Maxwell, Jia-Chi Wang, Douglas Rabin, Joseph Catanese, Renius Owen, Corey Braastad, Weimin Sun

Affiliations
1 Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
2 Athena Diagnostics, Marlborough, MA, USA
3 Celera Diagnostics, Alameda, CA, USA

Citation

Webpage
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0167130

References